Ibrance Illustrates Heavy FDA Workload For 'Breakthrough' Reviews
Executive Summary
Approval of Pfizer's breast cancer therapy palbociclib on the basis of Phase II data required an exhaustive set of statistical sensitivity analyses and a striking number of pre-NDA meetings.
You may also be interested in...
Pfizer’s Ibrance And The Realities Of 'Real-World' Evidence
US FDA approved expanded label for male breast cancer based on a supplement that included only non-traditional data sets. But agency is making clear that the “substantial” evidence for efficacy still came from the traditional pivotal trials – in women.
Surrogate Endpoints Only Have ‘Limited’ Evidence On Cancer Survival, Review Concludes
21st Century Cures legislation also criticized in JAMA Internal Medicine editorial.
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
FDA review documents for Sandoz’s filgrastim-sndz suggest that biosimilar sponsors need to consider how differences in delivery device from the reference product will play out under the 351(k) pathway, including whether new device designs and human factors data will be needed to secure interchangeability.